Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Background:This analysis evaluates the patient-reported outcomes (PROs) in two randomized studies of biosimilar LY2963016 insulin glargine (LY IGlar) and Lantus[R] insulin glargine (IGlar), when used in combination with mealtime insulin lispro in patients with type 1 diabetes mellitus (T1 DM) or ora...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	GaBI Journal 2018-06, Vol.7 (2), p.56-62
Hauptverfasser:	Perez-Nieves, Magaly, Pollom, Robyn K, Duan, Ran, Kabul, Samaneh, DeLozier, Amy M, Kaushik, Puneet, Ilag, Liza L
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood glucose Care and treatment Clinical trials Diabetes mellitus Diabetes therapy Hypoglycemic agents Insulin Medical research Patient outcomes Product development Type 1 diabetes Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!